DMT310, a novel once-weekly topical treatment for patients with moderate-to- severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo- controlled trial

Background: Poor patient adherence with antiacne medications is a common clinical challenge. DMT310, a natural, topical product with a once-weekly application schedule, may alleviate this obstacle.Objective: Evaluate the safety, tolerability, and efficacy of DMT310 in treating moderate-to-severe acne.Methods: This 12-week, randomized, double-blind, placebo-controlled, multicenter clinical trial enrolled participants 12 years and older with moderate-to-severe acne.Results: The intent-to-treat population included a total of 181 participants (DMT310, N = 91; placebo, N = 90). Participants who received DMT310 vs participants treated with placebo demonstrated a statistically significant greater reduction in the number of inflammatory and noninflammatory lesions at all time points: inflammatory lesion counts at week 12 (-15.64 vs -10.84, P < .001); noninflammatory lesion counts at week 12 (-18.26 vs -12.41, P <.001). DMT310-treated participants also had higher rates of Investigator's Global Assessment treatment success than participants in the placebo group at all time points: Investigator's Global Assessment at week 12 (44.40% vs 17.78%; P < .001). No serious treatment related adverse events occurred.Conclusions: DMT310 once-weekly topical treatment significantly reduced both inflammatory and noninflammatory lesions and yielded a greater proportion of Investigator's Global Assessment treatment success at all time points in participants with moderate-to-severe acne. ( J Am Acad Dermatol 2023;89:945-51.)

Automated summary

This study evaluated the safety, tolerability, and efficacy of DMT310 in treating moderate-to-severe acne. The results showed that DMT310 once-weekly topical treatment significantly reduced both inflammatory and noninflammatory lesions and had higher treatment success rates compared to the placebo group.